August 1, 2022 10:55 AM EDTUpdated August 5, 01:53 AM

Cash-strapped biotech flips ex-MedImmune anti-inflammatory drug for $15M cash

Amber Tong

Having turned to layoffs earlier this year to tighten its financial belt, microcap biotech Avalo Therapeutics has now added some much-needed cash to the bank …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cash-strapped biotech flips ex-MedImmune anti-inflammatory drug for $15M cash

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Cash-strapped biotech flips ex-Med­Im­mune an­ti-in­flam­ma­to­ry drug for $15M cash

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Cash-strapped biotech flips ex-MedImmune anti-inflammatory drug for $15M cash